ClinicalTrials.gg
CompletedNCT02493738Updated Mar 4, 2016

A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

A Phase 1 interventional study of Lozanoc 50mg and Sporanox 100mg in Superficial Mycoses, Dermatomycoses and Candidiasis, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-04.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

Study Objectives:

  • To evaluate the pharmacokinetics (PK) of orally administered Lozanoc under fasted and fed condition in healthy male subjects
  • To compare the pharmacokinetics (PK) of orally administered Lozanoc and Sporanox under fed condition in healthy male subjects
  • To evaluate the safety and tolerability of single oral dose of Lozanoc and Sporanox in Korean healthy male subjects
Read the detailed description

Phase I Study divided into 3 parts written as bellows.

Part I. Lozanoc 50mg single dose under fed condition vs Part 2. Lozanoc 50mg single dose under fasted condition vs Part 3. Sporanox 100mg single dose under fed condition

02

Conditions studied

  • Superficial Mycoses
  • Dermatomycoses
  • Candidiasis
  • Histoplasmosis
03

In context

Candidiasis

132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.

This study's enrollment of 24 is below the median of 91 across 86 interventional studies indexed under Candidiasis.

Browse Candidiasis studies →

Lead sponsor

Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Korean male volunteers in the age between 19 and 50 years old (inclusive)
  2. Subject who are able to give signed
  3. (BMI) in the range of 19 to 28 kg/m2 and weighting at least 50kg
  4. Subject who are considered

    • Pre-study physical examination with no abnormalities
    • No clinically significant medical history
    • Vital signs were to be within reference ranges, or if outside of the range, not deemed clinically significant in the opinion of the Investigator

      • 90 mmHg ≤ systolic blood pressure (sitting position) ≤ 140mmHg
      • 50 mmHg ≤ diastolic blood pressure (sitting position) ≤ 90 mmHg
    • Pre-study clinical laboratory findings were to be within reference range, or if outside of the range, not deemed clinically significant in the opinion of the Investigator
    • No clinically significant abnormalities in 12-lead results
  5. Agree to continue to use at least two accepted methods of and not to donate sperm for at least 1 days before the first dosing, during the course of the study and for a period of 90days following the last dosing.

    • Acceptable methods of birth control are: female (sexual partner) hormonal contraceptives; intrauterine device; surgical sterility at least 6 months prior to screening (Ex. hysterectomy, bilateral oophorectomy, and/or tubal ligation); use diaphragm; use condom; or spermicide

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded if they meet any of the following criteria:

  1. History of allergy or sensitivity to any drug, including any prior serious adverse reaction to antifungal agent(s)
  2. History of congestive heart failure or Patients with ventricular dysfunction such as congestive heart failure
  3. Undergone surgery or who have a medical condition, that in the judgment of the Investigator, may affect absorption, distribution, metabolism or elimination of the drug product
  4. Participated in a previous clinical trial within 90 days prior to screening visit
  5. Donated blood or had a significant loss of blood within 60 days prior to screening visit
  6. Special diet or substantial changes in eating habits within 30 days prior to screening visit
  7. Use of any prescription medication within 14 days before screening visit
  8. Use of any other OTC medication within the 7 days before screening visit
  9. History of smoking within 3 months prior to screening visit
  10. Have a recent history (within 2 years prior to the screening visit) of alcohol or drug abuse or a positive screen for drugs of abuse at screening
  11. Positive blood screen for or or C or syphilis
  12. abnormal hepatic function test (, ALT greater than 2 fold of reference upper limit (), or total greater than 1.5 x ULN)
  13. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Lozanoc 50mg

    Lozanoc 50mg, oral administration

    Drug: Lozanoc 50mg

  • Active comparator
    Sporanox 100mg

    Sporanox 100mg, oral administration

    Drug: Sporanox 100mg

Interventions

  • Lozanoc 50mg single dose under fed and fasted condition

  • Sporanox 100mg single dose under fed condition

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 0~120 hour after medication

Secondary outcomes

  1. tmax

    Time frame: 0~120 hour after medication

  2. AUCinf

    Time frame: 0~120 hour after medication

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2015
First posted
Jul 9, 2015
Start
Jul 2015
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Last update
Mar 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02493738
Responsible party
Sponsor
First posted
Jul 9, 2015
Start date
Jul 2015
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Mar 4, 2016

Study contacts

Kyun-Seop Bae, M.D., Ph.D.
principal investigator · Department of Clinical Pharmacology and Therapeutics, Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion